Actavis
Activis became a player in the rosacea treatment market after their acquisition of Allergan completed in March 2015. Allergan is developing a treatment for the redness of rosacea based on Oxymetazoline, currently called AGN-199201.
Recent Rosacea Blog Posts
Following on from the large trial announcement by Actavis last year, Galderma has started a suit against Actavis to prevent the sale of Generic Mirvaso. Actavis has filed an abbreviated new drug application with the FDA. Galderma is seeking to use a series of patents to block Actavis from marketing their Brimonidine Topical Gel, 0.33%. […]
An interesting development in rosacea clinical trials is the emergence of a new company called Actavis. Actavis have listed a large trial where they plan to test their Brimonidine Gel against Galderma’s recently FDA approved Brimonidine-based Mirvaso Gel. The large Phase 3 trial will compare the response after 7 days. Up to 462 patients in […]
